Opko Health, Inc. (OPK): Price and Financial Metrics

Opko Health, Inc. (OPK): $3.75

-0.13 (-3.35%)

POWR Rating

Component Grades













Add OPK to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • Value is the dimension where OPK ranks best; there it ranks ahead of 76.2% of US stocks.
  • OPK's strongest trending metric is Stability; it's been moving up over the last 48 weeks.
  • OPK's current lowest rank is in the Growth metric (where it is better than 7.31% of US stocks).

OPK Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.45 for Opko Health Inc; that's greater than it is for just 22.39% of US stocks.
  • Over the past twelve months, OPK has reported earnings growth of -165.32%, putting it ahead of merely 12.73% of US stocks in our set.
  • Revenue growth over the past 12 months for Opko Health Inc comes in at 97.8%, a number that bests 93.28% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to OPK, based on their financial statements, market capitalization, and price volatility, are MTRN, XRX, CW, VOXX, and PLPC.
  • Visit OPK's SEC page to see the company's official filings. To visit the company's web site, go to www.opko.com.

OPK Valuation Summary

  • OPK's EV/EBIT ratio is 26; this is 11.26% lower than that of the median Healthcare stock.
  • OPK's EV/EBIT ratio has moved up 31.6 over the prior 243 months.
  • Over the past 243 months, OPK's price/earnings ratio has gone up 43.8.

Below are key valuation metrics over time for OPK.

Stock Date P/S P/B P/E EV/EBIT
OPK 2021-08-31 1.4 1.5 37.1 26.0
OPK 2021-08-30 1.4 1.5 36.9 25.9
OPK 2021-08-27 1.4 1.5 37.1 26.0
OPK 2021-08-26 1.3 1.5 36.3 25.5
OPK 2021-08-25 1.4 1.5 36.7 25.8
OPK 2021-08-24 1.3 1.5 36.3 25.5

OPK Growth Metrics

  • Its 3 year net income to common stockholders growth rate is now at -353.89%.
  • Its year over year cash and equivalents growth rate is now at 159.2%.
  • The 5 year price growth rate now stands at -76.48%.
Over the past 33 months, OPK's revenue has gone up $948,197,000.

The table below shows OPK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1,910.311 107.853 70.907
2021-03-31 1,769.11 108.883 120.796
2020-12-31 1,435.413 39.476 30.586
2020-09-30 1,165.08 -40.819 -114.062
2020-06-30 965.788 -127.696 -199.786
2020-03-31 890.949 -166.904 -293.295

OPK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OPK has a Quality Grade of C, ranking ahead of 45.3% of graded US stocks.
  • OPK's asset turnover comes in at 0.781 -- ranking 31st of 677 Pharmaceutical Products stocks.
  • OCX, SRRA, and ITCI are the stocks whose asset turnover ratios are most correlated with OPK.

The table below shows OPK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.781 0.347 0.094
2021-03-31 0.730 0.368 0.140
2020-12-31 0.611 0.377 0.063
2020-09-30 0.505 0.384 -0.079
2020-06-30 0.418 0.392 -0.157
2020-03-31 0.380 0.362 -0.256

OPK Price Target

For more insight on analysts targets of OPK, see our OPK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.60 Average Broker Recommendation 1.2 (Strong Buy)

OPK Stock Price Chart Interactive Chart >

Price chart for OPK

OPK Price/Volume Stats

Current price $3.75 52-week high $6.27
Prev. close $3.88 52-week low $3.02
Day low $3.75 Volume 2,381,000
Day high $3.84 Avg. volume 5,367,590
50-day MA $3.70 Dividend yield N/A
200-day MA $4.16 Market Cap 2.55B

Opko Health, Inc. (OPK) Company Bio

Opko Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. The company was founded in 2005 and is based in Miami, Florida.

OPK Latest News Stream

Event/Time News Detail
Loading, please wait...

OPK Latest Social Stream

Loading social stream, please wait...

View Full OPK Social Stream

Latest OPK News From Around the Web

Below are the latest news stories about Opko Health Inc that investors may wish to consider to help them evaluate OPK as an investment opportunity.

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon, a once-weekly long-acting recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD) in pediatric patients. The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to Janu

Yahoo | September 24, 2021

GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes

GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced it has completed clinical genetic exome sequencing for more than 300,000 patients, making the company's dataset the largest of its kind in the world. Supported by matching phenotypes, the company's market-leading genomic analysis and interpretation capabilities have created a diagnosis and discovery engine advancing genetic medicine worldw

Yahoo | September 21, 2021

CEO And Chairman Of Opko Health Makes $346.44 Thousand Buy

Phillip Frost M.D., Individually And As Trustee, CEO And Chairman at Opko Health (NASDAQ:OPK), made a large insider buy on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Trustee purchased 100,000 shares of Opko Health at a price of $3.46 per share. The total transaction amounted to $346,443. Trustee now owns a total of 223,298,871 of Opko Health worth, 779,313,059. Opko Health shares are trading

Yahoo | September 15, 2021

OPKO Health (OPK) Forms JV, Establishes Presence in China

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

Yahoo | September 15, 2021

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories

SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company focused on diagnostics and pharmaceuticals, announce the formation of a joint venture to develop, manufacture and commercialize two of OPKO’s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, OPKO

Yahoo | September 14, 2021

Read More 'OPK' Stories Here

OPK Price Returns

1-mo -0.79%
3-mo -2.85%
6-mo -11.76%
1-year 16.46%
3-year 0.81%
5-year -66.09%
YTD -5.06%
2020 168.71%
2019 -51.16%
2018 -38.57%
2017 -47.31%
2016 -7.46%

Continue Researching OPK

Want to see what other sources are saying about Opko Health Inc's financials and stock price? Try the links below:

Opko Health Inc (OPK) Stock Price | Nasdaq
Opko Health Inc (OPK) Stock Quote, History and News - Yahoo Finance
Opko Health Inc (OPK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.871 seconds.